5 Key Takeaways

• 1

  Encelto, an encapsulated cell therapy, shows sustained effects in treating macular telangiectasia type 2 (MacTel) based on early real-world experience.

• 2

  Clinical trials indicated a 36% reduction in photoreceptor loss over 2 years, with functional benefits including a 68% reduction in monocular reading speed loss.

• 3

  Surgical techniques for Encelto implantation have evolved to minimize device-related complications, including refined suture mechanics and knot techniques.

• 4

  Safety findings in real-world use align with clinical trials, with about 20% of patients experiencing mild delayed dark adaptation and miosis.

• 5

  Patient selection is crucial, with younger patients and those with less ellipsoid zone loss identified as stronger responders to Encelto treatment.